Abstract:The gene editing technology enables cutting or/and inserting the target gene precisely. The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) system relies on two major elements, a guide RNA (gRNA) that recognizes a specific DNA sequence, and a nuclease Cas9 that cuts the target DNA and creates double-strand breaks (DSBs). Among a few gene-editing technologies available, CRISPR/Cas9 system has showed tremendous advantages over the others, mainly due to high efficiency of Cas9 and simple design of gRNA. As a versatile and powerful tool for genome engineering, the CRISPR/Cas9 technology has been used to generate genetically modified mice with unprecedented simplicity and speed, simply by timed delivery of Cas9/gRNA ribonucleoproteins (RNPs) into pronuclear-stage zygotes. The modified protocol introduces Cas9 protein instead of Cas9 mRNA by rapid electroporation, which enables the gene editing occurring before the first replication of the mouse genome, thus generating non-mosaic mutant embryos. Furthermore, it could be used to produce multiple gene mutations in a single mouse by co-delivering several gRNAs targeted to different genes. Herein, we summarize current applications of CRISPR/Cas9 technology in the field of neuroscience, and aim to provide concise information and perspectives for better utilizing this technology. In brain research, the CRISPR/Cas9 system can be applied either at the one-cell stage of the fertilized eggs in the form of Cas9/gRNA ribonucleoproteins, or at the stage of embryos or adults in the form of plasmid DNA or the viral vectors (commonly AAV variants) respectively. To deliver the system specifically into the developmental or adult brain, in utero electroporation, or stereotaxic injection is commonly employed. Several reports show that AAV-assisted Cas9/gRNA system could achieve a satisfied efficiency for genome editing in the adult mouse brain, but results vary depending on Cas9 activity, gRNA design, detection methods, and the condition of endogenous DNA repair mechanisms. Remarkable efforts have also been made to enhance the incidence of homology-directed repair for precise gene modifications. Regarding therapeutic genome editing, a couple of recent in vivo studies demonstrate that CRISPR/Cas9 system could contract or remove disease-causing alleles in animal models of certain hereditary diseases such as retinitis pigmentosa and Huntington′s disease, raising hope for translating therapeutic genome editing to clinical patients. In addition, we discuss major challenges and critical improvements for this technology, including a few modifications for promoting precise editing in non-dividing cells in the case of adult brain. In the future, application of CRISPR/Cas9 technology would be enhanced greatly in neuroscience by developing cell type-specific, timed delivery system in vivo and by combining with other powerful techniques for dissecting brain neural circuits in health and disease.

CRISPR interference-based specific and efficient gene inactivation in the brain

CRISPR/Cas9-Mediated Gene Knock-Down in Post-Mitotic Neurons

An Improved CRISPR/dCas9 Interference Tool for Neuronal Gene Suppression

Strategy for Applying CRISPR/Cas9 Gene Editing Technology in Neuroscience

Electrophysiological Study of Synaptotagmin I Deletion Using CRISPR/Cas9

A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation

In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9

Targeted gene silencing in the nervous system with CRISPR-Cas13

A Cre-Dependent CRISPR/dCas9 System for Gene Expression Regulation in Neurons

Highly efficient neuronal gene knockout in vivo by CRISPR-Cas9 via neonatal intracerebroventricular injection of AAV in mice

Conditional Gene Editing in Presynaptic Extinction-ensemble Cells via the CRISPR-SaCas9 System

Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins

Shortening the Half-Life of Cas9 Maintains Its Gene Editing Ability and Reduces Neuronal Toxicity.

In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease

CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes

CRISPR/cas9, a Novel Genomic Tool to Knock Down Microrna in Vitro and in Vivo.

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

Application of novel CRISPR tools in brain therapy

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases.

CRISPR Interference (crispri) for Sequence-Specific Control of Gene Expression

Supramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion